Philips Q3: 8% Order Intake Growth, 13.0% Adjusted EBITA Margin, EUR 288M DOJ Provision
PHG sits 23% above its 52-week low of $23.62 on elevated volume (2.2× avg).
Summary
Philips grew comparable orders 8% and sales 3% to EUR 4.4 billion in Q3, expanded the adjusted EBITA margin to 13.0%, and booked a EUR 288 million provision for an agreement in principle with the US DOJ over the Respironics recall while reiterating its 2026 outlook.
Key Events · Earnings and Guidance · PHG
-
Q3 Orders Up 8%, Sales Up 3%
Comparable order intake rose 8%, led by Diagnosis & Treatment, and comparable sales grew 3% to EUR 4,393 million from EUR 4,302 million a year earlier.
-
Margin Expands to 13.0%
Adjusted EBITA rose to EUR 569 million and the margin improved 70 basis points to 13.0%, with expansion in all three segments: Diagnosis & Treatment 12.3%, Connected Care 13.3%, Personal Health 17.7%.
-
EUR 288M DOJ Provision Hits Net Income
An agreement in principle with the US Department of Justice over the Respironics recall drove a EUR 288 million provision, cutting income from operations to EUR 165 million and net income to EUR 28 million; payment is expected in Q1 2027.
-
Free Cash Flow Jumps to EUR 384M
Operating cash flow reached EUR 544 million and free cash flow EUR 384 million in the quarter, versus EUR 172 million a year earlier; year-to-date free cash flow is EUR 635 million against negative EUR 688 million in 2025.
Analysis · PHG · Industrial Applications And Services
Philips delivered the operating quarter it needed: 8% comparable order intake growth and 3% comparable sales growth to EUR 4.4 billion, with the adjusted EBITA margin up 70 basis points to 13.0% and expansion in all three segments. The headline net income of EUR 28 million looks weak only because of a EUR 288 million provision for the agreement in principle with the US Department of Justice over the Respironics recall — a charge that resolves a multi-year legal overhang rather than reflecting operating deterioration. Cash generation was the standout: EUR 544 million from operations and EUR 384 million of free cash flow in the quarter, versus EUR 172 million a year earlier. Management reiterated the full-year outlook, and the Dutch court's refusal to order an investigation into the recall handling removes a second legal tail risk.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHG was trading at $29.01 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $26.7B. The 52-week trading range was $23.62 to $33.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.